Key result
Class V RBD-targeted MAbs localize to an invariant site of vulnerability and exhibit considerable breadth against divergent sarbecoviruses.
Why the study?
Neutralizing MAbs targeting the RBD without blocking ACE2 binding are of interest because the epitopes are well conserved across sarbecoviruses and exhibit cross-reactivity.
Population
SARS-CoV-2 and divergent sarbecoviruses
Design
Other
Authors
Loading...
Supports broad sarbecovirus countermeasures; leaves open clinical translation pending trials.
Class V RBD-targeted MAbs demonstrate broad cross-reactivity against sarbecoviruses, highlighting a conserved site of vulnerability for future vaccine and therapeutic development.
Jensen et al. (2023) studied COVID-19 / SARS-CoV-2. Class V RBD-targeted MAbs was evaluated. Class V RBD-targeted MAbs localize to an invariant site of vulnerability and exhibit considerable breadth against divergent sarbecoviruses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: